9-13 May 2012 • Barcelona, Spain - Estro-events.org

Pre re-M -Meeting eeting CCourses
ourses
CLInICaL PRe-MeeTIng COuRSe • WeDneSDaY, 9 MaY 2012
InnOVaTIOn In IMagIng ReLeVanT FOR THe RaDIaTIOn OnCOLOgISTS anD THe RaDIOLOgISTS
Jointly organised with ESOR
course dIrectors:
P. Lambin (nL) and L. Marti-bonmarti (eS)
course aIms:
This course, jointly organized by eSTRO and eSOR (european School of Radiology), aims at promoting an integrated approach
between specialists involved in multidisciplinary tumour boards to tailor the best treatment for each individual
patient by exploiting the use of imaging.
new advanced imaging technology not only provides morphological information on tumour extension, but also information
on tumour function and biology. It not only allows a good evaluation of tumour response during and after treatment,
but also an early detection of tumour recurrence. Radiation oncologists increasingly use hybrid equipment in which
diagnostic imaging technology is incorporated within the radiation treatment machines to allow continuous adaptation
of radiation treatment according to the daily response of the tumour, the surrounding organs and their movement.
Thus there is a growing interest to enhance the collaboration between imaging specialists to optimise and to adapt the
different uses of imaging to the comprehensive clinical management of the oncological patient.
by the combination of lectures and case discussions, this course aims to offer a programme focusing on the use of imaging
in a truly multidisciplinary environment to support understanding between different specialists’ needs, practising
common language and delineating research perspectives.
Who should attend?
The target group consists of radiation oncologists and senior residents and junior radiologists who are interested in
learning and improving their knowledge on an optimal approach to multidisciplinary treatment management exploiting
the use of imaging.
content:
• Innovation in hardware: PeT- MR, dual energy CT,
• Quantification of imaging: standardisation in PeT, diffusion MR, quantification of response, how to get more out of
imaging,
• What do we need to know in a multidisciplinary tumour board? Head and neck cancer, lung cancer, prostate cancer,
rectum cancer.
RaDIObIOLOgY PRe-MeeTIng COuRSe • WeDneSDaY, 9 MaY 2012
ESTRO
31
2012
COMbInIng RaDIaTIOn WITH TaRgeTeD THeRaPIeS: COnCePTS, OPPORTunITIeS anD PITFaLLS
course dIrectors:
C. Vens (nL) and a. Chalmers (gb)
course aIms:
Research into the mechanisms underlying resistance of tumours to radiation therapy has identified a number of key pathways
that could be targeted in order to improve tumour control. and advances in drug development have provided us
with new drugs to manipulate these pathways. but only a few of these targeted agents have been successfully combined
with radiation therapy in the clinic, and the results have been mixed. The aim of this course is to provide an overview of
the key concepts and pathways involved, and to discuss progress made and problems encountered in bringing radiation/
targeted therapy combinations to the clinic.
Who should attend the course?
The course is targeted at radiation oncologists who may be aware of the existence of targeted therapies, and may even
have prescribed them, but would like to learn more. In particular we will try to explain why and how these agents can
be combined with radiation therapy. Research or scientific experience is not required, but the course will also be of
interest to scientists undertaking radiation related research.
content:
The course will provide an overview of targeted therapy concepts in four areas that are relevant to radiation responses
of tumours:
• Dna damage responses (including Dna repair and cell cycle checkpoints),
• Signal transduction pathways (including egFR, PI3K and related pathways),
• Tumour microenvironment (including hypoxia, integrins and cancer stem cells),
• angiogenesis.
There will then be a session on how to determine which patients are likely to benefit from which combinations. This
will include aspects of biomarker development including imaging, pathology, clinical features and molecular subtyping.
The final session will focus on clinical application of these concepts. Here we will consider what we have learned from
those clinical trials that have been conducted – both positive and negative – and how we can select the best drugs and
design the best clinical studies. The course will finish with a vision of the future in which combinations of radiation and
targeted therapies are considered to be ‘standard of care’.
a panel of invited international speakers will provide high quality talks that are specifically tailored to our target audience.
In between talks there will be lots of opportunities (and much encouragement) for spirited discussion involving
faculty and delegates.
Page 6 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 7